Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?

Where are BARD1's shares hiding?

| More on:
A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The BARD1 Life Sciences Limited (ASX: BD1) share price isn't going anywhere on Thursday.

In fact, the BARD1 share price has vanished completely from the ASX boards today.

Where is the BARD1 share price?

The good news is that nothing bad has happened to the BARD1 share price or the company itself.

The reason you can't see it on the ASX boards is because this morning the company's name and ticker change came into effect.

Following the approval of shareholders at its annual general meeting at the end of November, the diagnostic and exosome-based products company has now renamed itself INOVIQ Ltd (ASX: IIQ).

Why did BARD1 become INOVIQ?

The company changed its name to INOVIQ as it feels this better reflects the strategic vision, broader intellectual property assets, and its expanded product portfolio since its acquisition of Sienna Cancer Diagnostics in 2020.

This is because the original name of BARD1 related to its BARD1 technology and doesn't reflect its broader interests across other technologies such as the SubB2M, NETs and hTERT.

INOVIQ's CEO, Dr Leearne Hinch, explained: "The name change to INOVIQ represents the evolution of the Company's expanded focus on developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The new name future-proofs the continued growth and expansion of our business, capabilities, and product portfolio. We thank shareholders for their support of the name change and look forward to unveiling the new brand and website in coming weeks."

Prior to the name change, the BARD1 share price was up approximately 59% in 2021. Investors will no doubt be hoping the INOVIQ share price picks up from where BARD1 left off.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »